What is Microdermics?
Microdermics is a specialized medical technology firm dedicated to revolutionizing drug delivery for both the biopharmaceutical industry and end-users. The company's core value proposition lies in its proprietary microneedle injection system, an innovative alternative to conventional hypodermic needles. By focusing on a scalable and versatile platform, Microdermics aims to enhance patient comfort while simultaneously improving the efficiency of drug administration. The company operates at the intersection of advanced materials science and healthcare, providing biopharma partners with a customizable solution that addresses the complexities of modern drug delivery. Their market position is defined by a commitment to replacing invasive procedures with high-precision, user-friendly technology that meets the rigorous standards of the global healthcare landscape.
How much funding has Microdermics raised?
Microdermics has raised a total of $1M across 1 funding round:
Unspecified
$1M
Unspecified (2017): $1M with participation from K5 Ventures and Shoreline Ventures
Key Investors in Microdermics
K5 Ventures
K5 Ventures is an early-stage startup accelerator and venture capital fund based in California, focusing on game-changing innovations and funding for exceptional products and teams.
Shoreline Ventures
Shoreline Venture Management LLC is a venture capital firm headquartered in Vancouver and San Francisco, specializing in early-stage tech startups and healthcare IT.
What's next for Microdermics?
Looking ahead, the strategic deployment of this capital will likely focus on accelerating the commercialization of the microneedle platform and expanding manufacturing capabilities to meet anticipated demand. As the company moves beyond its initial development phase, the focus will shift toward securing partnerships with major biopharmaceutical entities and navigating the regulatory pathways required for widespread clinical adoption. The backing from experienced venture capital firms provides not only the necessary liquidity for scaling operations but also the operational expertise required to navigate the competitive landscape of medical device innovation. Future growth will be contingent upon the successful integration of their technology into existing drug delivery pipelines and the continued validation of their platform's efficacy in diverse therapeutic applications.
See full Microdermics company page
